ArticleInvestigational new drugs2018

New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations.

Elisabetta Bigagli et al.PubMed ↗Publisher ↗

No numbers read from the abstract.